title: Adherence to treatment of osteoporosis: a need for study.
abstract: Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis.
  
  
  BACKGROUND
  Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients.
  
  
  METHODS
  An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting.
  
  
  RESULTS
  The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence.
  
  
  CONCLUSIONS
  Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement.
authors.forename: F
authors.initials: F
authors.lastname: Lekkerkerker
authors.forename: J A
authors.initials: JA
authors.lastname: Kanis
authors.forename: N
authors.initials: N
authors.lastname: Alsayed
authors.forename: G
authors.initials: G
authors.lastname: Bouvenot
authors.forename: N
authors.initials: N
authors.lastname: Burlet
authors.forename: D
authors.initials: D
authors.lastname: Cahall
authors.forename: A
authors.initials: A
authors.lastname: Chines
authors.forename: P
authors.initials: P
authors.lastname: Delmas
authors.forename: R-L
authors.initials: RL
authors.lastname: Dreiser
authors.forename: D
authors.initials: D
authors.lastname: Ethgen
authors.forename: N
authors.initials: N
authors.lastname: Hughes
authors.forename: J-M
authors.initials: JM
authors.lastname: Kaufman
authors.forename: S
authors.initials: S
authors.lastname: Korte
authors.forename: G
authors.initials: G
authors.lastname: Kreutz
authors.forename: A
authors.initials: A
authors.lastname: Laslop
authors.forename: B
authors.initials: B
authors.lastname: Mitlak
authors.forename: V
authors.initials: V
authors.lastname: Rabenda
authors.forename: R
authors.initials: R
authors.lastname: Rizzoli
authors.forename: A
authors.initials: A
authors.lastname: Santora
authors.forename: R
authors.initials: R
authors.lastname: Schimmer
authors.forename: Y
authors.initials: Y
authors.lastname: Tsouderos
authors.forename: P
authors.initials: P
authors.lastname: Viethel
authors.forename: J-Y
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012107:Research Design; D012646:Self Administration
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates